title: Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
abstract: Inflammatory myofibroblastic tumor (IMT) is a distinctive mesenchymal neoplasm characterized by a spindle-cell proliferation with an inflammatory infiltrate. Approximately half of IMTs carry rearrangements of the anaplastic lymphoma kinase (ALK) locus on chromosome 2p23, causing aberrant ALK expression. We report a sustained partial response to the ALK inhibitor crizotinib (PF-02341066, Pfizer) in a patient with ALK-translocated IMT, as compared with no observed activity in another patient without the ALK translocation. These results support the dependence of ALK-rearranged tumors on ALK-mediated signaling and suggest a therapeutic strategy for genomically identified patients with the aggressive form of this soft-tissue tumor. (Funded by Pfizer and others; ClinicalTrials.gov number, NCT00585195.).
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA 02115, USA.
authors.forename: James E
authors.initials: JE
authors.lastname: Butrynski
authors.forename: David R
authors.initials: DR
authors.lastname: D'Adamo
authors.forename: Jason L
authors.initials: JL
authors.lastname: Hornick
authors.forename: Paola
authors.initials: P
authors.lastname: Dal Cin
authors.forename: Cristina R
authors.initials: CR
authors.lastname: Antonescu
authors.forename: Suresh C
authors.initials: SC
authors.lastname: Jhanwar
authors.forename: Marc
authors.initials: M
authors.lastname: Ladanyi
authors.forename: Marzia
authors.initials: M
authors.lastname: Capelletti
authors.forename: Scott J
authors.initials: SJ
authors.lastname: Rodig
authors.forename: Nikhil
authors.initials: N
authors.lastname: Ramaiya
authors.forename: Eunice L
authors.initials: EL
authors.lastname: Kwak
authors.forename: Jeffrey W
authors.initials: JW
authors.lastname: Clark
authors.forename: Keith D
authors.initials: KD
authors.lastname: Wilner
authors.forename: James G
authors.initials: JG
authors.lastname: Christensen
authors.forename: Pasi A
authors.initials: PA
authors.lastname: Jänne
authors.forename: Robert G
authors.initials: RG
authors.lastname: Maki
authors.forename: George D
authors.initials: GD
authors.lastname: Demetri
authors.forename: Geoffrey I
authors.initials: GI
authors.lastname: Shapiro
mesh_terms: D000008:Abdominal Neoplasms / Q000188:drug therapy* / Q000235:genetics; D000328:Adult; D000077548:Anaplastic Lymphoma Kinase; D000077547:Crizotinib; D006104:Granuloma, Plasma Cell / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D008297:Male; D009154:Mutation; D009379:Neoplasms, Muscle Tissue / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics*; D019859:Proto-Oncogene Proteins c-met / Q000037:antagonists & inhibitors; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases; D017978:Receptors, Growth Factor / Q000037:antagonists & inhibitors; D055815:Young Adult
chemical_list: D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D017978:Receptors, Growth Factor; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; C491743:MET protein, human; D011505:Protein-Tyrosine Kinases; D019859:Proto-Oncogene Proteins c-met; D020794:Receptor Protein-Tyrosine Kinases